Bora Pharmaceuticals’ Bobby Sheng wins ‘CEO of the Year’ at CPhI Awards 2020

October 15, 2020

- Oct 15, 2020 - Bora Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO) which specialises in immediate and modified-release tablets and capsules, along with serialised packaging, announced that its Chairman and CEO, Bobby Sheng, was unveiled as ‘CEO of the Year’ at the CPhI Pharma Awards 2020.

The CEO of the Year award is granted to the C-suite executive who is able to demonstrate exemplary leadership skills to drive forward their organization, displaying an ability to increase performance, engage staff and customers, whilst also being committed to the development of the wider pharma industry.

Chosen from a shortlist of seven candidates, Bobby was awarded the accolade due to his fulfilment of these criteria and for being a ‘trailblazer’ in both the Taiwanese and Global market.

The judges noted that the performance of Bora Pharmaceuticals, under his leadership, “has elevated the overall pharma market,” with Bobby recently guiding the company through ‘pivotal changes’ that demonstrated his abilities as a ‘top CEO’. 

This year, Bobby successfully oversaw the expansion of Bora Pharmaceuticals from Asia into the US. This ensured the company met its ambitious international growth goals, despite the backdrop of the COVID-19 crisis. With his expertise and charismatic leadership, Bobby is playing an instrumental role in putting Taiwan on the map at the centre of global pharmaceutical quality and excellence.

Bora Pharmaceuticals is currently experiencing continued demand for its CDMO services in North America, Asia, and Europe, and is nearing completion of its planned acquisition of a GSK’s facility in Mississauga, Canada

Sheng, said: “Winning such a prestigious award is an incredible acknowledgement not just of me, but of the work, values and expertise of the whole team at Bora Pharmaceuticals. I am incredibly proud of the growth we have achieved thanks to the excellent customer service, technical agility, and niche capabilities that the team at Bora provide to our customers across North America, Asia and Europe.”
The award ceremony, which has been held annually since 2004, is organised to highlight the innovation taking place across the industry, by individuals and companies, and is voted on by an independent judging panel of senior industry experts from around the world. The winners of the awards were announced via an online ceremony, during the CPhI Festival of Pharma, held on the 13th of October 2020.

For more information about Bora Pharmaceuticals’ service offerings, please visit: https://cdmo.bora-corp.com


- ENDS -
For further information, images and interview opportunities with Bora, please contact Jalna Maharjan| jalna.maharjan@ramarketingpr.com | +44 (0)191 222 1242 | www.ramarketingpr.com | www.twitter.com/ramarketingpr

About Bora CDMO

Bora is a leading contract development and manufacturing organisation (CDMO) that specialises in complex modified release drug product manufacturing and solvent processing for non-sterile oral solid dosage forms.
Employing over 475 people across its two state-of-the-art facilities in Taiwan, the CDMO has the agility and expertise to take on challenging projects, offering tailored solutions for niche drug product requirements.

The publicly listed company is supported by several investors and shareholders such as UMC and Taishin Financial Holdings.